吉西他滨联合奥沙利铂治疗晚期复发性卵巢癌的临床观察  

Efficacy observation of gemcitabine and oxaliplatin therapy in recurrent advanced ovarian carcinoma

作　　者：骆梅青[1] 康马飞[1] 廖漓漓[1] 刘瑛[1] 

机构地区：[1]桂林医学院附属医院肿瘤内科,广西桂林541001

出　　处：《现代医药卫生》2011年第1期17-18,共2页Journal of Modern Medicine & Health

摘　　要：目的:探讨吉西他滨联合奥沙利铂治疗晚期复发性卵巢癌的临床疗效及不良反应。方法:24例复发性晚期卵巢癌患者,其中铂类敏感复发转移10例,铂类耐药复发转移14例。所有患者均予国产吉西他滨1 000 mg/m2第1,8天静脉给药;奥沙利铂100 mg/m2,第一天静脉给药。3周为1周期,2个周期后评价疗效。结果:总有效率为29.1%,其中铂类敏感复发患者为40.0%,铂类耐药复发患者为21.4%,中位疾病进展时间为6.9个月,中位生存期为17.6个月。主要不良反应为骨髓抑制和胃肠道反应,Ⅲ度白细胞下降和Ⅲ度血小板减少发生率分别为为16.7%和25%。结论:吉西他滨联合奥沙利铂治疗晚期复发性卵巢癌疗效确切,毒性可耐受。Objective：To evaluate the effects of gemcitabine and oxaliplatin on treating recurrent advanced ovarian carcinoma and their adverse reactions.Methods：A total of 24 patients with recurrent advanced ovarian carcinoma were enrolled,including 10 cases of platinum-sensitive and 14 cases of platinum-resistant.All patients were treated with intravenous gemcitabine 1000 mg/m2 on 1d and 8 d,and intravenous oxaliplatin 100 mg/m2 on 1d.3 weeks was 1 cycle.The efficacy was evaluated after 2 cycles.Results：The overall response rate（ORR） was 29.1%,the effective rate was 40.0% for platinum-sensitive and 21.4% for platinum-resistant respectively.Median TTP and overall survival were 6.9months and 17.6 months respectively.The main toxicities were myelosuppression and nausea and vomit.Grade 3 neutropenia and thrombocytopenia were 16.7% and 25% respectively.Conclusion：Gemcitabine combined with oxaliplatin is effective to treat recurrent advanced ovarian carcinoma with tolerable toxicity.

关 键 词：卵巢肿瘤 化学治疗 吉西他滨 奥沙利铂 

分 类 号：R73[医药卫生—肿瘤]